Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) and Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.
Risk & Volatility
Ocular Therapeutix has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Contineum Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500.
Institutional and Insider Ownership
59.2% of Ocular Therapeutix shares are held by institutional investors. 3.1% of Ocular Therapeutix shares are held by insiders. Comparatively, 7.9% of Contineum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ocular Therapeutix | $51.95 million | 43.27 | -$265.94 million | ($1.42) | -7.21 |
| Contineum Therapeutics | $50.00 million | 10.48 | -$59.98 million | ($1.73) | -8.05 |
Contineum Therapeutics has lower revenue, but higher earnings than Ocular Therapeutix. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Ocular Therapeutix and Contineum Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ocular Therapeutix | -579.10% | -59.89% | -45.99% |
| Contineum Therapeutics | N/A | -24.73% | -23.51% |
Analyst Recommendations
This is a summary of recent ratings and target prices for Ocular Therapeutix and Contineum Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ocular Therapeutix | 1 | 1 | 11 | 0 | 2.77 |
| Contineum Therapeutics | 1 | 1 | 4 | 0 | 2.50 |
Ocular Therapeutix currently has a consensus target price of $25.75, suggesting a potential upside of 151.59%. Contineum Therapeutics has a consensus target price of $20.80, suggesting a potential upside of 49.30%. Given Ocular Therapeutix’s stronger consensus rating and higher possible upside, analysts clearly believe Ocular Therapeutix is more favorable than Contineum Therapeutics.
Summary
Ocular Therapeutix beats Contineum Therapeutics on 9 of the 14 factors compared between the two stocks.
About Ocular Therapeutix
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company’s sustained-release hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
About Contineum Therapeutics
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.
